Chronic Obstructive Pulmonary Disease (COPD) is a significant healthcare problem, with an estimated 384 million cases worldwide in 2010.1 Population aging is predicted to drive further growth, with one study forecasting a 150% increase in prevalence overall, and up to 220% in the 75 and over age group, between 2010 and 2030.
Trudell ramps up production of AEROCOUNT® Dose Indicator in preparation to supply Forest Laboratories, Inc. with commercial volumes to support their CFC to HFA transition on Flunisolide Inhalation Aerosol. London, Canada
London, Canada (23-September-08) – Trudell Medical International is pleased to announce the selection of the AEROCOUNT® Dose Indicator for use with Forest’s proprietary product containing the active ingredient Flunisolide in an HFA formulation.
AEROCOUNT® Dose Indicator integrated with the Alvesco® (ciclesonide) Inhalation Aerosol for the U.S. Market
London, Canada (7-May-08) - Trudell Medical International is pleased to announce the FDA approval of Alvesco® (ciclesonide) inhalation aerosol in combination with the AEROCOUNT® Dose Indicator. Alvesco, a novel inhaled corticosteroid, will be distributed in the U.S. by Sepracor Inc. under an agreement with Nycomed based in Europe.